Short answer:
Once it’s on the market, generic ruxolitinib is expected to cost roughly 20 – 30 % of the brand‑name price. That translates to a monthly bill that’s typically $300–$400 instead of the $800–$1,200 you see with Jakafi® (the brand), and an annual cost of about $3,600–$4,800 versus $9,600–$14,400. In other words, you could save on the order of $5–$10 k per year—but the exact savings depend on your insurance, copay tiers, and the pharmacy you use.
---
1. Why the difference?
| Item | Brand (Jakafi®) | Generic (anticipated) |
|------|-----------------|------------------------|
| Price per 50 mg vial | ~$750–$800 | ~$75–$100 |
| Typical monthly dose | 2–4 vials (depending on severity) | 2–4 vials |
| Monthly out‑of‑pocket (average) | $800–$1,200 | $300–$400 |
| Annual out‑of‑pocket (average) | $9,600–$14,400 | $3,600–$4,800 |
| Discount vs. brand | 0 % | 70–80 % off |
The generic price is driven by lower manufacturing costs (no brand‑building marketing, R&D amortization) and competition among generic manufacturers once the patent expires.
---
2. Current status in the U.S. and abroad
| Region | Generic availability | Expected launch year |
|--------|----------------------|----------------------|
| United States | Not yet approved (patent pending for some indications) | 2025–2026 (post‑patent expiry) |
| European Union | Approved (under the name Ruxol®) | 2024 |
| Canada | Generic approval in 2025 | 2025 |
Because the U.S. generics haven’t hit the shelves yet, the numbers above are projections based on EU pricing data, early reports from generic manufacturers, and typical discount patterns seen with other oncology drugs.
---
3. How it plays out for patients
1. Insurance & Formulary
* Most Medicare Part D and Medicaid plans cover Jakafi® under a preferred tier, but the copay is still $80–$120/month.
* Once generic is available, it will usually drop to a lower tier (often $10–$30/month copay), making it much cheaper for the patient.
2. Manufacturer Rebates
* Brand manufacturers negotiate rebates with pharmacy benefit managers (PBMs). Generic manufacturers usually offer smaller rebates (if any), so the net price difference can be even larger than the sticker price difference.
3. Patient Assistance Programs (PAPs)
* For brand, the company runs PAPs that can cover up to 75 % of the cost for uninsured patients.
* Generics generally don’t offer PAPs, but the out‑of‑pocket cost is so low that most patients won’t need them.
---
4. What to keep in mind
| Factor | Impact on cost |
|--------|----------------|
| Dose & frequency | Higher disease burden → more vials → higher total cost; savings scale linearly. |
| Insurance plan | Some plans lock patients into brand until generic is added; others may immediately switch. |
| Pharmacy location | Independent pharmacies sometimes charge higher prices; discount programs can reduce out‑of‑pocket. |
| State Medicaid | Some states negotiate state‑wide rebates that further lower the effective price. |
---
5. Bottom line
- Brand price: ~$1,000–$1,200/month (≈$12–$14k/year).
- Generic price: ~$300–$400/month (≈$3.6–$4.8k/year).
- Savings: Roughly $5–$10k annually, or 70–80 % off the brand cost.
When generic ruxolitinib finally lands on U.S. shelves, it will dramatically reduce the financial burden for patients and payers alike. If you’re currently paying for Jakafi®, check with your pharmacy or PBM to see if they’ve switched to a generic tier yet—sometimes the savings can be immediate. If you’re planning a future prescription, the generic version will almost certainly be the more cost‑efficient choice.